Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + Androgen Ablation + Radiotherapy in High-Risk Prostate Cancer
NCT04947254Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2021
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in prostate cancer (PCa), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2021; status: recruiting.
02
Drugs
niraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04947254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947254.